Acticor Biotech (STU:7V7) Debt-to-Equity : 19.15 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Debt-to-Equity?

Acticor Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €2.71 Mil. Acticor Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €4.34 Mil. Acticor Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €0.37 Mil. Acticor Biotech's debt to equity for the quarter that ended in Jun. 2023 was 19.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Acticor Biotech's Debt-to-Equity or its related term are showing as below:

STU:7V7' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.51 Med: 0.42 Max: 19.15
Current: 19.15

During the past 6 years, the highest Debt-to-Equity Ratio of Acticor Biotech was 19.15. The lowest was -3.51. And the median was 0.42.

STU:7V7's Debt-to-Equity is ranked worse than
99.44% of 1062 companies
in the Biotechnology industry
Industry Median: 0.145 vs STU:7V7: 19.15

Acticor Biotech Debt-to-Equity Historical Data

The historical data trend for Acticor Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Debt-to-Equity Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.19

0.13

1.49

0.25

-3.51

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial				1.12	0.25	0.60	-3.51	19.15

Competitive Comparison of Acticor Biotech's Debt-to-Equity

For the Biotechnology subindustry, Acticor Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acticor Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's Debt-to-Equity falls into.

Acticor Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Acticor Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.801	+	7.062)	/	-2.243
	=	-3.51

Acticor Biotech's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.705	+	4.342)	/	0.368
	=	19.15

Acticor Biotech (STU:7V7) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Acticor Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (STU:7V7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (STU:7V7) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ALACT:France

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (STU:7V7) Headlines

No Headlines